Interferon alpha-induced lupus: Proof of principle

Journal of Clinical Rheumatology

Volumn 14, Issue 3, 2008, Pages 131-132

  Niewold, Timothy B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; INTERFERON REGULATORY FACTOR 5; LA ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN KINASE TYK2; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; AUTOIMMUNITY; CELL ACTIVATION; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG INDUCED DISEASE; EDITORIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS C; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOASSAY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; VIRUS IMMUNITY; BLOOD; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; NOTE;

ANTIVIRAL AGENTS; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 48249136616     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318177627d     Document Type: Editorial

References (18)

1. Ho V, Mclean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol. 2008;14:166 -168.
2. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 2006;8:907-922.
3. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979; 301:5-8.
4. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003;100:2610-2615.
5. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294:1540-1543.
6. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227:207-210.
7. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178-181.
8. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003;36:511-518.
9. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-142.
10. Bell TM, Bansal AS, Shorthouse C, et al. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol. 1999;14:419-422.
11. Conlon KC, Urba WJ, Smith JW 2nd, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 1990;65:2237-2242.
12. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503.
13. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006;3:e491.
14. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502.
15. Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet. 2005;76:528-537.
16. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA. 2007;104: 6758-6763.
17. Sigurdsson S, Goring HH, Kristjansdottir G, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet. 2008;17:872-881.
18. Niewold TB, Kelly JA, Crow MK, et al. IRF5 risk haplotype is associated with high serum interferon alpha activity in systemic lupus erythematosus patients. Ann Rheum Dis. 2008;67(suppl):A44.